The Biden-Harris administration has introduced a proposed rule aimed at preventing pharmaceutical companies from circumventing Medicare drug price negotiations by adding new active ingredients to existing medications. The Centers for Medicare and Medicaid Services (CMS) intends to finalize the selection process for the next 20 drugs subject to price negotiation by February 1, 2027, with the resulting prices slated to take effect in 2029.
Why the CMS is targeting "line extensions"
The administration’s proposal addresses a practice known as "line extension," where manufacturers introduce a new version of an existing drug—such as a different dosage or a slightly modified active ingredient—to reset the clock on federal price negotiations. According to the Department of Health and Human Services (HHS), current law requires Medicare to wait seven years for small-molecule drugs and 11 years for biologics after FDA approval before initiating price negotiations.
By closing potential loopholes, the CMS aims to ensure that pharmaceutical companies cannot delay the impact of the Inflation Reduction Act (IRA), which granted Medicare the authority to negotiate prices for some of the costliest drugs on the market.
How the Medicare negotiation timeline functions
Medicare’s ability to negotiate drug prices is strictly governed by the time elapsed since the drug’s initial FDA approval. The process follows a specific statutory schedule:
- Small-Molecule Drugs: Eligible for negotiation seven years after FDA approval.
- Biologics: Eligible for negotiation 11 years after FDA approval.
The proposed rule seeks to clarify how the CMS identifies "qualifying single-source drugs." By defining these categories more strictly, the agency hopes to prevent manufacturers from using minor modifications to shield products from the negotiation process. The CMS previously considered these regulatory adjustments in 2023 but elected to conduct further analysis before moving forward with the formal proposal.
What happens next for drug pricing
The proposed rule is currently undergoing a public comment period, a standard procedure for federal rulemaking. Once the comment period concludes, the CMS will review industry feedback and internal data to finalize the criteria for the next round of drug selections.
The selection of the next 20 drugs is scheduled for announcement on February 1, 2027. These drugs will be subject to negotiations throughout 2027 and 2028, with the new, lower prices scheduled to hit the market in 2029. This effort is part of a broader federal push to reduce out-of-pocket costs for Medicare beneficiaries, who often face high expenses for specialty medications and biologics.
Key Considerations for Medicare Beneficiaries
The shift in policy reflects a significant change in how the federal government interacts with the pharmaceutical industry. While the industry has historically utilized FDA-approved modifications to extend the exclusivity of their products, the CMS is now prioritizing the reach of the IRA to ensure that long-standing, high-cost drugs do not remain exempt from price oversight.
For patients, the primary benefit of these negotiations is the potential for reduced copays and lower overall spending on prescription drugs. However, the impact will remain limited to the specific list of drugs selected by the CMS under the criteria established by the final rule.
Keep reading